48 results
SC 14D9/A
PRDS
Pardes Biosciences Inc
17 Aug 23
Tender offer solicitation (amended)
5:09pm
to the winding down of the Company’s research and development activities, minus (v) $400,000, which is the expense cap under the CVR Agreement, minus (vi … determined to suspend further clinical development of pomotrelvir, wind down research and development activities in an orderly manner, implement
CORRESP
PRDS
Pardes Biosciences Inc
17 Aug 23
Correspondence with SEC
12:00am
development of pomotrelvir, wind down research and development activities in an orderly manner, implement a substantial reduction in force and initiate
SC 14D9
PRDS
Pardes Biosciences Inc
28 Jul 23
Tender offer solicitation
5:04pm
and business plans with a view towards identifying potential opportunities to increase stockholder value, taking into account Pardes’ research and development … to suspend further clinical development of pomotrelvir, wind down research and development activities in an orderly manner, implement a substantial
8-K
EX-2.1
PRDS
Pardes Biosciences Inc
17 Jul 23
Entry into a Material Definitive Agreement
7:06am
by regulating the research, development, manufacturing or distribution of these products.
“IND” means an Investigational New Drug Application submitted … related to the winding down of the Company’s research and development activities consistent with the Company’s intentions described in its press release
8-K
EX-99.1
5m7eer9ggi4kba eg4zb
5 May 23
Pardes Biosciences Reports First Quarter 2023 Financial Results
4:02pm
8-K
hvdvc3je7v
3 Apr 23
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
8:00am
424B3
jzuy9p ln
7 Nov 22
Prospectus supplement
4:14pm
8-K
EX-99.1
ixyowe8 l6ffr
7 Nov 22
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
4:00pm
424B3
51eae0v4cvo5yn
15 Aug 22
Prospectus supplement
5:41pm
8-K
EX-99.1
oc11 mzns
15 Aug 22
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8:06am
424B3
euf9qo23d09dr9by9
10 May 22
Prospectus supplement
4:35pm
8-K
EX-99.1
nraj6bb7klvd3oehsef
10 May 22
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
DEF 14A
birg8icn
26 Apr 22
Definitive proxy
6:07am
424B3
5k07ec49gu7t7mm
1 Apr 22
Prospectus supplement
4:01pm